WO2016177862A1 - Heterocyclic compounds and their use in preventing or treating bacterial infections - Google Patents
Heterocyclic compounds and their use in preventing or treating bacterial infections Download PDFInfo
- Publication number
- WO2016177862A1 WO2016177862A1 PCT/EP2016/060142 EP2016060142W WO2016177862A1 WO 2016177862 A1 WO2016177862 A1 WO 2016177862A1 EP 2016060142 W EP2016060142 W EP 2016060142W WO 2016177862 A1 WO2016177862 A1 WO 2016177862A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mmol
- oxo
- alkyl
- diazabicyclo
- oct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 *C(CN(C1)C2=O)=C(*)C1N2O* Chemical compound *C(CN(C1)C2=O)=C(*)C1N2O* 0.000 description 8
- YCUWZRTWPPTYSN-UHFFFAOYSA-N C=CCON(C(CN1C2)C=C2I)C1=O Chemical compound C=CCON(C(CN1C2)C=C2I)C1=O YCUWZRTWPPTYSN-UHFFFAOYSA-N 0.000 description 2
- VUSLYGKUDDJMMC-UHFFFAOYSA-N Brc1nc(cccn2)c2[s]1 Chemical compound Brc1nc(cccn2)c2[s]1 VUSLYGKUDDJMMC-UHFFFAOYSA-N 0.000 description 1
- GTDZRCHHWHXSRA-LPRJTOQXSA-N C/C=C/[P+](c1ccccc1)(c1ccccc1)c1ccccc1 Chemical compound C/C=C/[P+](c1ccccc1)(c1ccccc1)c1ccccc1 GTDZRCHHWHXSRA-LPRJTOQXSA-N 0.000 description 1
- YDSKVLKPSPLMJR-UHFFFAOYSA-N C=CCON(C(CN1C2)C=C2[n]2nccc2)C1=O Chemical compound C=CCON(C(CN1C2)C=C2[n]2nccc2)C1=O YDSKVLKPSPLMJR-UHFFFAOYSA-N 0.000 description 1
- GRZVOLIUUZNDHQ-UHFFFAOYSA-N C=CCON(C(CN1C2)C=C2c2nc3cccnc3[s]2)C1=O Chemical compound C=CCON(C(CN1C2)C=C2c2nc3cccnc3[s]2)C1=O GRZVOLIUUZNDHQ-UHFFFAOYSA-N 0.000 description 1
- IPISOFJLWYBCAV-UHFFFAOYSA-N CC(C)(C)OC([n]1ncc(B2OC(C)(C)C(C)(C)O2)c1)=O Chemical compound CC(C)(C)OC([n]1ncc(B2OC(C)(C)C(C)(C)O2)c1)=O IPISOFJLWYBCAV-UHFFFAOYSA-N 0.000 description 1
- HBUGYHQXBLSYTI-UHFFFAOYSA-N CC(C)(C)OC([n]1ncc(C(CN(C2)C3=O)=CC2N3OCC=C)c1)=O Chemical compound CC(C)(C)OC([n]1ncc(C(CN(C2)C3=O)=CC2N3OCC=C)c1)=O HBUGYHQXBLSYTI-UHFFFAOYSA-N 0.000 description 1
- BOXDNKOICZGEDY-UHFFFAOYSA-N CC1(C)OB(C(C(C2)N3OCC=C)=CCN2C3=O)OC1(C)C Chemical compound CC1(C)OB(C(C(C2)N3OCC=C)=CCN2C3=O)OC1(C)C BOXDNKOICZGEDY-UHFFFAOYSA-N 0.000 description 1
- WDVMUEQOMCJSTO-UHFFFAOYSA-O CC=C[PH+](c1ccccc1)c1ccccc1 Chemical compound CC=C[PH+](c1ccccc1)c1ccccc1 WDVMUEQOMCJSTO-UHFFFAOYSA-O 0.000 description 1
- NOLXTJIJIGRFJA-UHFFFAOYSA-N CCC(C=NN1C)=CC1=O Chemical compound CCC(C=NN1C)=CC1=O NOLXTJIJIGRFJA-UHFFFAOYSA-N 0.000 description 1
- KDZJDTWUSLHWQN-UHFFFAOYSA-N CN(C(C=C1)=O)N=C1Br Chemical compound CN(C(C=C1)=O)N=C1Br KDZJDTWUSLHWQN-UHFFFAOYSA-N 0.000 description 1
- ABFLRVCAGVUXDU-UHFFFAOYSA-N CN1N=CC(C(C(C2)N3OCC=C)=CCN2C3=O)=CC1=O Chemical compound CN1N=CC(C(C(C2)N3OCC=C)=CCN2C3=O)=CC1=O ABFLRVCAGVUXDU-UHFFFAOYSA-N 0.000 description 1
- YLUVXTBLSQNNSB-UHFFFAOYSA-N C[Sn](C)(C)C(CN(C1)C2=O)=CC1N2OCC=C Chemical compound C[Sn](C)(C)C(CN(C1)C2=O)=CC1N2OCC=C YLUVXTBLSQNNSB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- any nitrogen atom present within a heterocycle or present within group wherein it is trisubstituted thus forming a tertiary amino group, can be further quaternized by a methyl group.
- T 1 represents an unsubstituted or substituted by one or more T 2 , (C C 3 )-alkyl; (CH 2 ) m OQ 1 , -(CH 2 ) m -C(0)NQ 1 Q 2 ; (CH 2 ) m C(0)OQ 1 , (CH 2 ) m NQ 1 Q 2 , wherein T 2 , m Q 1 and Q 2 are as defined above.
- base addition salts include ammonium salts such as tromethamine, meglumine, epolamine, etc, metal salts such as sodium, lithium, potassium, calcium, zinc or magnesium salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine.
- suitable salts may be found in Remington's Pharmaceutical Sciences, 17 th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, P.H. Stahl, C.G. Wermuth, Handbook of Pharmaceutical salts - Properties, Selection and Use, Wiley-VCH, 2002 and S.M. Berge et al. "Pharmaceutical Salts" J. Pharm. Sci, 66: p.1 -19 (1977).
- Reaction mixture was filtered on celite®, washed with MeOH (50 mL). The filtrate was diluted with EtOAc (250 mL) and cooled down to 0 °C. 0.1 M aqueous hydrochloric acid was added to reach pH 5-6. Aqueous layer was extracted with EtOAc (3 x 75 mL). Combined organic layers were dried over Na 2 S0 4 , filtered and concentrated under reduced pressure.
- Step 1 preparation of intermediate 6-allyloxy-4-(2-methylpyrazol-3-yl)-1 ,6- diazabicyclo[3.2.11oct-3-en-7-one (2a)
- step 6 the intermediate 6-allyloxy-4- (oxazol-2-yl)-1 ,6-diazabicyclo[3.2.1 ]oct-3-en-7-one (4a) (71 mg, 0.287 mmol) is converted into triphenyl-(propenyl)-phosphonium [4-(oxazol-2-yl)-7-oxo-1 ,6-diazabicyclo[3.2.1 ]oct-3- en-6-yl] sulfate (4b) as an amorphous solid after purification by flash chromatography on silica gel (DCM/acetone from 80/20 to 10/90).
- DCM/acetone from 80/20 to 10/90
- Step 2 preparation of intermediate triphenvHpropenvD-phosphonium [4-(3-pyridyl)-7- oxo-1 ,6-diazabicvclof3.2.1 loct-3-en-6-yll sulfate (9b)
- step 1 the intermediate (6-allyloxy-4- (4,4,5, 5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,6-diazabicyclo[3.2.1]oct-3-en-7-one (8a) (50 mg, 0.163 mmol) is converted into 6-allyloxy-4-(2-pyridyl)-1 ,6-diazabicyclo[3.2.1]oct-3- en-7-one (11a) (19 mg, 0.074 mmol, 45%) using 2-bromopyridine (31 mg, 0.196 mmol), PEPPSI catalyst (22 mg, 0.032 mmol) and after purification by chromatography on silica gel (DCM/acetone 100/0 to 80/20).
- 2-bromopyridine 31 mg, 0.196 mmol
- PEPPSI catalyst 22 mg, 0.032 mmol
- step 6 the intermediate 6-allyloxy-4- (pyrazin-2-yl)-1,6-diazabicyclo[3.2.1]oct-3-en-7-one (12a) (57 mg, 0.220 mmol) was converted into triphenyl-(propenyl)-phosphonium [4-(pyrazin-2-yl)-7-oxo-1 ,6- diazabicyclo[3.2.1]oct-3-en-6-yl] sulfate (12b) as an amorphous solid which was used in the next step without purification.
- Step 3 preparation of sodium [4-(1 -methyl-2-oxo-4-pyridyl)-7-oxo-1 .6- diazabicvclo[3.2.1 loct-3-en-6-yll sulfate (Example 13)
- Step 1 preparation of intermediate 6-allyloxy-4-(1-methyl-6-oxo-pyridazin-3-yl)-1,6- diazabicvclo[3.2.11oct-3-en-7-one (17a)
- Example 33 synthesis of sodium [3-(4-pyridyl)-7-oxo-1 ,6-diazabicyclo[3.2.11oct-3-en-6-yl1 sulfate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2983674A CA2983674A1 (en) | 2015-05-07 | 2016-05-06 | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| BR112017023359A BR112017023359A2 (pt) | 2015-05-07 | 2016-05-06 | ?compostos, composições farmacêuticas e kits? |
| KR1020177031802A KR102713561B1 (ko) | 2015-05-07 | 2016-05-06 | 헤테로사이클릭 화합물 및 세균성 감염을 예방 또는 치료하는 이의 용도 |
| US15/571,964 US10183943B2 (en) | 2015-05-07 | 2016-05-06 | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| CN201680026527.9A CN107580595B (zh) | 2015-05-07 | 2016-05-06 | 杂环化合物及它们在预防或治疗细菌感染中的应用 |
| RU2017135321A RU2741496C2 (ru) | 2015-05-07 | 2016-05-06 | Гетероциклические соединения и их применение в лечении или предотвращении бактериальных инфекций |
| EP16725377.2A EP3292125B1 (en) | 2015-05-07 | 2016-05-06 | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| JP2017558028A JP6767392B2 (ja) | 2015-05-07 | 2016-05-06 | 複素環式化合物及び細菌感染の治療又は予防におけるその使用 |
| AU2016257338A AU2016257338B2 (en) | 2015-05-07 | 2016-05-06 | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| NZ736152A NZ736152B2 (en) | 2016-05-06 | Heterocyclic compounds and their use in preventing or treating bacterial infections | |
| MX2017014080A MX2017014080A (es) | 2015-05-07 | 2016-05-06 | Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas. |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305701.3 | 2015-05-07 | ||
| EP15305701.3A EP3091018A1 (en) | 2015-05-07 | 2015-05-07 | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| EP16305144 | 2016-02-08 | ||
| EP16305144.4 | 2016-02-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2016177862A1 true WO2016177862A1 (en) | 2016-11-10 |
Family
ID=56083989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2016/060142 Ceased WO2016177862A1 (en) | 2015-05-07 | 2016-05-06 | Heterocyclic compounds and their use in preventing or treating bacterial infections |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10183943B2 (enExample) |
| EP (1) | EP3292125B1 (enExample) |
| JP (1) | JP6767392B2 (enExample) |
| KR (1) | KR102713561B1 (enExample) |
| CN (1) | CN107580595B (enExample) |
| AU (1) | AU2016257338B2 (enExample) |
| BR (1) | BR112017023359A2 (enExample) |
| CA (1) | CA2983674A1 (enExample) |
| CL (1) | CL2017002803A1 (enExample) |
| MX (1) | MX2017014080A (enExample) |
| RU (1) | RU2741496C2 (enExample) |
| TW (1) | TWI754613B (enExample) |
| WO (1) | WO2016177862A1 (enExample) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9883867B2 (en) | 2015-07-14 | 2018-02-06 | Atricure, Inc. | Surgical tool |
| EP3301094A1 (en) * | 2016-09-30 | 2018-04-04 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| EP3300736A1 (en) * | 2016-09-30 | 2018-04-04 | Mutabilis | Composition comprising antibiotic compound and an heterocyclic compound and their use in preventing or treating bacterial infections |
| EP3357924A1 (en) | 2017-02-06 | 2018-08-08 | Mutabilis | Novel heterocyclic compounds and their use in preventing or treating bacterial infections |
| US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| US12378244B2 (en) | 2018-08-09 | 2025-08-05 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine β-lactamases |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002010172A1 (fr) * | 2000-08-01 | 2002-02-07 | Aventis Pharma Sa | Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens |
| WO2013150296A1 (en) * | 2012-04-02 | 2013-10-10 | Astrazeneca Ab | Heterobicyclic compounds as beta-lactamase inhibitors |
| WO2013181741A1 (en) | 2012-06-04 | 2013-12-12 | Elkimia | Imino compounds as protecting agents against ultraviolet radiations |
| US20140315876A1 (en) * | 2013-03-15 | 2014-10-23 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2835186B1 (fr) * | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
| JP5038509B2 (ja) * | 2008-01-18 | 2012-10-03 | メルク・シャープ・エンド・ドーム・コーポレイション | β−ラクタマーゼ阻害剤 |
| CN103649088B (zh) * | 2011-08-30 | 2016-05-11 | 沃克哈特有限公司 | 1, 6- 二氮杂双环[3, 2, 1]辛- 7- 酮衍生物及其在治疗细菌感染中的用途 |
| TW201343645A (zh) * | 2012-03-30 | 2013-11-01 | Cubist Pharm Inc | １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑 |
| WO2015059643A1 (en) * | 2013-10-22 | 2015-04-30 | Wockhardt Limited | Pharmaceutical compositions comprising antibacterial agents |
| CA2980085A1 (en) * | 2015-03-31 | 2016-10-06 | Mutabilis | Novel heterocyclic compounds and their use in preventing or treating bacterial infections |
-
2016
- 2016-05-06 CN CN201680026527.9A patent/CN107580595B/zh active Active
- 2016-05-06 KR KR1020177031802A patent/KR102713561B1/ko active Active
- 2016-05-06 TW TW105114242A patent/TWI754613B/zh not_active IP Right Cessation
- 2016-05-06 RU RU2017135321A patent/RU2741496C2/ru active
- 2016-05-06 BR BR112017023359A patent/BR112017023359A2/pt not_active Application Discontinuation
- 2016-05-06 JP JP2017558028A patent/JP6767392B2/ja active Active
- 2016-05-06 US US15/571,964 patent/US10183943B2/en active Active
- 2016-05-06 MX MX2017014080A patent/MX2017014080A/es unknown
- 2016-05-06 EP EP16725377.2A patent/EP3292125B1/en active Active
- 2016-05-06 WO PCT/EP2016/060142 patent/WO2016177862A1/en not_active Ceased
- 2016-05-06 CA CA2983674A patent/CA2983674A1/en active Pending
- 2016-05-06 AU AU2016257338A patent/AU2016257338B2/en not_active Ceased
-
2017
- 2017-11-06 CL CL2017002803A patent/CL2017002803A1/es unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002010172A1 (fr) * | 2000-08-01 | 2002-02-07 | Aventis Pharma Sa | Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens |
| WO2013150296A1 (en) * | 2012-04-02 | 2013-10-10 | Astrazeneca Ab | Heterobicyclic compounds as beta-lactamase inhibitors |
| WO2013181741A1 (en) | 2012-06-04 | 2013-12-12 | Elkimia | Imino compounds as protecting agents against ultraviolet radiations |
| US20140315876A1 (en) * | 2013-03-15 | 2014-10-23 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
Non-Patent Citations (9)
| Title |
|---|
| "Handbook of Chemistry and Physics, 76th Edition,", 1995, CRC PRESS, INC., pages: 2-25 - 2-26 |
| "Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY |
| "Remington's Pharmaceutical Sciences, 17th ed.,", 1985, MACK PUBLISHING COMPANY, pages: 1418 |
| GENNARO, A. R.,: "Remington: The Science and Practice of Pharmacy, 20th ed.;", 2000, LIPPINCOTT WILLIAMS & WILKINS |
| GILMAN ET AL: "The pharmacological basis of therapeutics, 8th ed.,", 1990, PERGAMON PRESS |
| P.H. STAHL; C.G. WERMUTH: "Handbook of Pharmaceutical salts - Properties, Selection and Use", 2002, WILEY-VCH |
| RAHWAY, N.J.: "Merck Index", MERCK & COMPANY |
| S.M. BERGE ET AL.: "Pharmaceutical Salts", J. PHARM. SCI, vol. 66, 1977, pages 1 - 19 |
| TETRAHEDRON LETT., vol. 35, 1994, pages 3589 - 3592 |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9883867B2 (en) | 2015-07-14 | 2018-02-06 | Atricure, Inc. | Surgical tool |
| AU2017335222C1 (en) * | 2016-09-30 | 2022-01-20 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| EP3300736A1 (en) * | 2016-09-30 | 2018-04-04 | Mutabilis | Composition comprising antibiotic compound and an heterocyclic compound and their use in preventing or treating bacterial infections |
| WO2018060484A1 (en) * | 2016-09-30 | 2018-04-05 | Mutabilis | Composition comprising antibiotic compound and an heterocyclic compound and their use in preventing or treating bacterial infections |
| WO2018060481A1 (en) * | 2016-09-30 | 2018-04-05 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| US10722520B2 (en) | 2016-09-30 | 2020-07-28 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| AU2017335222B2 (en) * | 2016-09-30 | 2021-07-15 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| EP3301094A1 (en) * | 2016-09-30 | 2018-04-04 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| EP4086255A1 (en) * | 2016-09-30 | 2022-11-09 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| EP3357924A1 (en) | 2017-02-06 | 2018-08-08 | Mutabilis | Novel heterocyclic compounds and their use in preventing or treating bacterial infections |
| WO2018141986A1 (en) | 2017-02-06 | 2018-08-09 | Mutabilis | Novel heterocyclic compounds and their use in preventing or treating bacterial infections |
| US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| US12378244B2 (en) | 2018-08-09 | 2025-08-05 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine β-lactamases |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017135321A (ru) | 2019-04-10 |
| JP6767392B2 (ja) | 2020-10-14 |
| NZ736152A (en) | 2024-09-27 |
| CN107580595B (zh) | 2020-09-18 |
| CL2017002803A1 (es) | 2018-05-11 |
| AU2016257338B2 (en) | 2020-03-05 |
| CA2983674A1 (en) | 2016-11-10 |
| KR20180002650A (ko) | 2018-01-08 |
| AU2016257338A1 (en) | 2017-10-26 |
| CN107580595A (zh) | 2018-01-12 |
| TW201643165A (zh) | 2016-12-16 |
| MX2017014080A (es) | 2018-07-06 |
| TWI754613B (zh) | 2022-02-11 |
| RU2017135321A3 (enExample) | 2019-08-13 |
| US10183943B2 (en) | 2019-01-22 |
| US20180093985A1 (en) | 2018-04-05 |
| BR112017023359A2 (pt) | 2018-07-17 |
| JP2018515504A (ja) | 2018-06-14 |
| KR102713561B1 (ko) | 2024-10-08 |
| EP3292125A1 (en) | 2018-03-14 |
| RU2741496C2 (ru) | 2021-01-26 |
| EP3292125B1 (en) | 2019-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102537340B1 (ko) | 베타-락타마제 억제제 화합물 | |
| EP3277277B1 (en) | Heterocyclic compounds and their use in preventing or treating bacterial infections | |
| AU2016257338B2 (en) | Heterocyclic compounds and their use in preventing or treating bacterial infections | |
| KR102691642B1 (ko) | 헤테로사이클릭 화합물 및 이의 박테리아 감염의 예방 또는 치료 용도 | |
| EP3277686B1 (en) | Novel heterocyclic compounds and their use in preventing or treating bacterial infections | |
| TW201815390A (zh) | 包含抗生素化合物及雜環化合物之組合物及其於預防或治療細菌感染之用途 | |
| AU2016239207A1 (en) | Heterocyclic compounds and their use in preventing or treating bacterial infections | |
| JP7589139B2 (ja) | 複素環式化合物及び細菌感染の予防又は治療へのそれらの使用 | |
| EP3091018A1 (en) | Heterocyclic compounds and their use in preventing or treating bacterial infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16725377 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2017135321 Country of ref document: RU |
|
| ENP | Entry into the national phase |
Ref document number: 2983674 Country of ref document: CA |
|
| ENP | Entry into the national phase |
Ref document number: 2016257338 Country of ref document: AU Date of ref document: 20160506 Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 20177031802 Country of ref document: KR Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2017/014080 Country of ref document: MX |
|
| ENP | Entry into the national phase |
Ref document number: 2017558028 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 15571964 Country of ref document: US |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2016725377 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017023359 Country of ref document: BR |
|
| ENP | Entry into the national phase |
Ref document number: 112017023359 Country of ref document: BR Kind code of ref document: A2 Effective date: 20171030 |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 736152 Country of ref document: NZ |